NCT05797662 - A Study of Propranolol to Treat Kaposi Sarcoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

August 1, 2028

Study Completion Date

August 1, 2029

Conditions

Kaposi Sarcoma

Interventions

DRUG

Propranolol

Adults: Propanolol 120 mg tablets by mouth twice daily for up to 24 weeks Children: Propanolol 3 mg/kg suspension, divided dose twice daily for up to 24 weeks

Trial Locations (9)

14080

Instituto Nacional de Cancerologia, Mexico City

Unknown

Fundación Huésped, Buenos Aires

Complexo Hospitalar Universitário Professor Edgard Santos, Salvador

Moi University School of Medicine, Eldoret

UNC Project Malawi, Lilongwe

African Cancer Institute at Stellenbosch, Cape Town

Uganda Cancer Institute, Kampala

University of Zimbabwe College of Health Sciences, Harare

20231-050

Instituto Nacional de Câncer José de Alencar, Rio de Janeiro

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

AIDS Malignancy Consortium

NETWORK